Search
More than science: the European Affairs program at EHA2023
To develop and administer safe, innovative and effective treatments for patients with blood diseases, hematologists need an effective and enabling regulatory environment.
Read moreBENIGN HEMATOLOGY in 2023 and beyond
The term "benign hematology" has traditionally been used to refer to non-malignant blood disorders. However, over the past few years, questions have been raised as to the appropriate nomenclature for this category of diseases.
Read morePrecision Hematology
The Precision Hematology Topics-in-Focus program will promote innovative concepts for diagnostics and innovative clinical trial designs, which should translate into the clinical application of precision hematology.
Read moreCarrerasLeaders call two is now open
The second CarrerasLeaders call is open: apply now to the postdoctoral program to empower future leaders in the fight against blood cancers.
Read moreEHA response to the EU’s Pharma Revision
Last week, the European Affairs team finalised EHA's response to the proposed revision of the EU (European Union) Pharmaceutical Legislation. In April 2023, the European Commission published a proposed Directive and Regulation to replace the current, outdated legal framework.
Read moreHelping to shape Europe’s clinical trials landscape: EHA selected for ACT EU advisory group
Improving the design, efficiency and effectiveness of clinical trials is the objective of the Accelerating Clinical Trials in the European Union (ACT EU) initiative.
Read more